alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 351–375 of 443 studies in Inflammation and the immune system · free to read (page 15 of 18) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 443 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

What “Inflammation and the immune system” covers

Inflammation and the immune system — The brain's immune cells and inflammatory signals, and their role in how Alzheimer's starts and progresses.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Fluids and Barriers of the CNS 2025-06-03

AMS-17 treatment improved cognitive function, enhanced blood-brain barrier (BBB) integrity, and promoted remyelination in VaD mice. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroinflammation in vascular cognitive impairment and dementia: Insights from clinical biomarkers and experimental models

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Cerebral Blood Flow & Metabolism 2026-04-10

Vascular cognitive impairment and dementia (VCID) encompasses a heterogeneous group of disorders in which cerebrovascular pathology contributes to cognitive decline. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Assessing the Roles of Aging, Estrogen, Nutrition, and Neuroinflammation in Women and Their Involvement in Alzheimer’s Disease—A Narrative Overview

✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Molecular Sciences 2026-01-26

The purpose of this narrative review is to examine women's cognitive health and to highlight its association with four major pillars: (1) aging, (2) estrogen decline and loss, (3) diet, and (4) neuroinflammation, and their contribution to cognitive decline, with a focus on this combination to increase awareness and address the progression and potential amelioration of Alzheimer's disease (AD). 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglial histone H3K18 crotonylation promotes STAT1 expression and induces cognitive deficit in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Immunology 2026-01-27

Hippocampal pan-histone H3 crotonylation (H3Kcr) and H3K18cr were significantly upregulated in both 5xFAD and Aβ42-injected mice compared to controls. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chronic caffeine consumption prevents obesity-induced cognitive and memory impairments by reducing neuroinflammation and enhancing neuronal activity in the hippocampus

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Pharmacological Research 2026-02-13

Obesity and its associated metabolic disturbances increase the risk of cognitive decline, dementia, and anxiety-related disorders. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies

✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Molecular Sciences 2025-12-07

Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are the two most common forms of dementia due to neurodegeneration. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

18F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Yonsei medical journal 2022-03-01

The results of the present study suggest that increased 18 F-THK5351 uptake might be a useful predictor of poor prognosis among Aβ- aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498). 3 key findings →

Design: clinical trial Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The American journal of pathology 1997-10-01

Entry of the type 1 human immunodeficiency virus into most cells requires the presence of the CD4 protein in combination with one of several recently described co-receptors. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Subtle Alterations in Hippocampal Neuronal Activity Coincide With Early Sex‐Specific Differences in Amyloidosis and Microglia in a Pre‐Symptomatic Mouse Model of Alzheimer‐Like Pathology

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Glia 2025-04-30

Growing evidence highlights sex-related differences in the pathogenesis of Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Monoamine Oxidase‐B (MAO‐B) Identifies Neurotoxic Reactive Astrocytes in Alzheimer's Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Compared to controls, MAO-B immunoreactive area fraction was significantly increased in the frontal cortex and white matter of AD, CBD, and especially PiD and FTLD-TDP, but not PSP. 5 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disrupted Calcium Dynamics in Reactive Astrocytes Occur with End Feet–Arteriole Decoupling in an Amyloid Mouse Model of Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Neuroscience 2025-08-15

While cerebrovascular dysfunction and reactive astrocytosis are extensively characterized hallmarks of Alzheimer's disease (AD) and related dementias, the dynamic relationship between reactive astrocytes and cerebral vessels remains poorly understood. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Navigation Between Alzheimer’s Disease (AD) and Its Various Pathophysiological Trajectories: The Pathogenic Link to Neuroimmunology—Genetics and Neuroinflammation

✓ Peer-reviewed alzhub usefulness score 40 out of 100. International Journal of Molecular Sciences 2025-08-26

One hundred and eighteen years have passed since Alzheimer's disease (AD) was first diagnosed by Alois Alzheimer as a multifactorial and complex neurodegenerative disorder with psychiatric components. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electrical stimulation of the vagus nerve improves amyloid pathology in delirium superimposed on dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Bioelectronic Medicine 2026-01-16

In AD-like mice surgery induced acute changes in amyloid-β; perioperative treatment with pVNS effectively reduced amyloid-β load, plaque sphericity, and neuronal loss. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regulating factors for microglial activation

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biological & pharmaceutical bulletin 2002-08-01

Microglia, residential macrophages in the central nervous system, can release a variety of factors including cytokines, chemokines, etc. to regulate the communication among neuronal and other types of glial cells. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Actin dynamics and cofilin-actin rods in alzheimer disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cytoskeleton (Hoboken, N.J.) 2016-03-01

Cytoskeletal abnormalities and synaptic loss, typical of both familial and sporadic Alzheimer disease (AD), are induced by diverse stresses such as neuroinflammation, oxidative stress, and energetic stress, each of which may be initiated or enhanced by proinflammatory cytokines or amyloid-β (Aβ) peptides. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Reduction of Neuroinflammation as a Common Mechanism of Action of Anorexigenic and Orexigenic Peptide Analogues in the Triple Transgenic Mouse Model of Alzheimer´s Disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neuroimmune Pharmacology 2025-02-11

It primarily affects cerebral regions responsible for cognition, memory, and language processing, significantly impeding the functional independence of patients. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ethanol induces neuroimmune dysregulation and soluble TREM2 generation in a human iPSC neuron, astrocyte, microglia triculture model

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alcohol 2025-11-07

Alcohol use disorders (AUDs) affect substantial populations worldwide and increase the risk of developing cognitive impairments and alcohol-associated dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events